UroGen Pharma (URGN) traded above the average analyst 12-month target of $44.75, last changing hands at $46.43 (+3.8%). The move implies the stock has surpassed analyst expectations, but the article provides no update to earnings, guidance, or fundamentals.
UroGen Pharma (URGN) traded above the average analyst 12-month target of $44.75, last changing hands at $46.43 (+3.8%). The move implies the stock has surpassed analyst expectations, but the article provides no update to earnings, guidance, or fundamentals.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
